Tissue Collection Framework To Improve Outcomes In Solid Tumours

NCT03572192 | Recruiting

• 1 other identifier: 9094QM
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Cancer therapies have significantly improved over the last decades, allowing cancer specialists to keep cancer under control for longer than ever before. However, metastatic cancer still develops in a large number of patients and drug resistance occurs in the majority of them after an initial period of response and leads to cancer progression and death. Aims: To date, the mechanisms which allow cancer cells to spread through the body to form metastases and to become resistant even to the most powerful treatments are poorly understood. Our aim is to collect cancer specimens and normal tissue specimens such as blood from patients with solid tumours and to analyse these samples with some of the latest molecular profiling technologies in the research laboratory. This comprehensive analysis should reveal what molecular defects fuel the growth of cancer cells adn what allows them to spread through the body and then develop resistance to cancer therapies. Such insights could subsequently lead to the development of better more improved treatments which prevent drug resistance, to novel molecular tests which can also predict which treatment is most likely to be effective and tolerable in individual patients. Methods: To achieve this, we aim to collect multiple samples from consenting patients starting from the diagnosis of a tumour to the time drug resistance develops more. Importantly, this study will collect tissues from interventional procedures which are performed as part of routine patient management of patients seen at Barts Health NHS trust. We will then apply molecular tests such as proteomics and DNA sequencing to these samples. Tissues which are left over after these tests have been applied will be stored in a licensed tissue bank to allow future research with novel technologies.

Conditions

Solid Tumours

Outcome Measures

Primary Outcomes (1)

• Identification of molecular determinants of drug resistance, tumour progression or treatment toxicity.

  30years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

solid tumours

You may qualify if:

• Male and female patients over the age of 18 years who have been diagnosed with a solid tumour and who are seen at the Barts Health NHS Trust for clinical management of their tumour.
• Male or female more than 18 years of age
• Able to participate in the study.
• Able to give informed consent.
• Patients enrolled into other clinical trials may be included into this study

You may not qualify if:

• Any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the study
• Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
• Physical or mental health issues that preclude them from participation

Sponsors & Collaborators

• Queen Mary University of London: lead

Study Sites (1)

St Bartholomew's Hospital

London, EC1A 7BE, United Kingdom

RECRUITING

Central Study Contacts

Thomas Powles

CONTACT

0207 882 8762; bci-orchidtrials@qmul.ac.uk

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 18, 2018
• First Posted: June 28, 2018
• Study Start: September 1, 2013
• Primary Completion (Estimated): August 1, 2043
• Study Completion (Estimated): August 1, 2043
• Last Updated: November 18, 2025

Record last verified: 2025-11

Locations

GB (1)